
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZNF784 (zinc finger protein 784) encodes a zinc finger protein with sequence-specific double-stranded DNA-binding activity. It is predicted to regulate RNA polymerase II-dependent transcription and may participate in differentiation of hematopoietic progenitor cells. The protein is predicted to function in the nucleus, where it may regulate gene expression through interactions with specific DNA regulatory regions.
Human normal colonic epithelial cells are represented by NCM460, a cell line derived from normal colonic mucosa rather than a malignant tumor. The cells are classified as human intestinal epithelial cells and are commonly used as a non-tumorigenic intestinal epithelial model.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_203374
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?